With the progress of medical technology, cloning hematopoietic was found to be widely exist in normal people. Because of its clinical significance and prognosis is unclear, it is named clonal hematopoiesis of indeterminate potential(CHIP), which has been detected in blood diseases such as myelodysplastic syndrome and lymphoma, and proven to be related to poor prognosis. Recently, CHIP has been also detected in patients with multiple myeloma (MM). In this article, the definition and influencing factors of CHIP, clinical significance, prognosis and treatment in MM were reviewed.
题目: 潜质未定的克隆性造血在多发性骨髓瘤中的研究进展.
摘要: 随着诊疗技术的进步，克隆性造血被发现广泛存在于正常人体内，因其临床意义以及预后尚不明确，被命名为潜质未定的克隆性造血（clonal hematopoiesis of indeterminate potential，CHIP），目前已经在骨髓增生异常综合征、淋巴瘤等血液疾病中被检测到，并证明与不良预后有关，近期相关报道显示在多发性骨髓瘤（MM）患者中也检测到CHIP的存在。本文拟对CHIP的定义和影响因素以及在MM中的临床意义、预后和治疗研究的最新进展作一综述.
Keywords: cardiovascular disease; clonal hematopoiesis; lenalidomide; multiple myeloma; treatment.